ADVA
ADVA (FSE: ADV) today announced that Colocation Australia (ColoAU), a subsidiary of 5G Networks Limited (ASX: 5GN), has deployed its FSP 3000 OpenFabric™ to give customers flexible and low-cost connectivity with complete freedom to adjust capacity as required. The company’s new national wavelength product uses bandwidth sourced from a range of providers to offer cost-effective long-distance transport. By using ADVA’s open OTN cross-connect technology, ColoAU is now able to optimize links between Australia’s mainland state capital cities and Singapore to offer the lower-speed services that businesses need. Customers can select data rates ranging from 1.25Gbit/s to 50Gbit/s over OTN, Ethernet, SDH/SONET and Fibre Channel interfaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005020/en/
“We’re using ADVA’s technology to solve one of the key problems that small and medium-sized companies face. They no longer need to waste valuable resources in overprovisioning links that end up redundant or obsolete and are able to support growing bandwidth requirements driven by demand. By utilizing the ADVA FSP 3000 OpenFabric™, we’re able to provide elastic bandwidth offerings that can instantly be turned up or down,” said Nic Tippelt, wholesale manager, ColoAU. “Our new national wavelength product lets customers take control. It empowers them to choose high-quality, secure, point-to-point connectivity that supports ever-changing capacity needs.”
The ADVA FSP 3000 OpenFabric™ gives ColoAU and 5GN Wholesale a truly scalable end-to-end architecture and the ability to support a wide range of client interfaces for metro, inter-capital or international connectivity. It enables the company to leverage other service provider and utility networks as its own and offer a unique combination of high capacity and flexibility. The ADVA FSP 3000 OpenFabric™ features open OTN switching technology , which extends the delivery of bandwidth services throughout the network and eliminates the boundaries of legacy OTN solutions. With the new service, ColoAU has become the first company to use the openness, flexibility and scalability of ADVA’s solution in this way.
“Our FSP 3000 OpenFabric™ creates an architecture that’s open, disaggregated and completely future-proof. It gives ColoAU’s customers the freedom to efficiently transport any mix of optical services, and scale as and when needed. By utilizing other networks to flexibly offer a wide range of wavelengths, the company is empowering enterprises across Australia to harness the ideal connectivity for their business needs,” commented Erik Lindberg, VP, sales, APAC, ADVA. “ColoAU’s new national wavelength product provides businesses across Australia and Singapore with an entirely new way to access the capacity they require. It enables them to seize new opportunities without major risk and eliminates wasted capacity and unnecessary cost.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About 5G Networks and Colocation Australia
Colocation Australia is a subsidiary company of 5G Networks. 5G Networks (ASX: 5GN) is a licenced telecommunications carrier operating across Australia. Our mission is to be Australia’s partner of choice for unifying a seamless digital experience for our customers across data connectivity, cloud and data centre services, underpinned by expert managed services in the business and wholesale markets. 5G Networks currently owns and operates its own nationwide highspeed data network with points of presence in all major Australian capital cities. www.5gnetworks.com.au .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005020/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom